Prelude Therapeutics (PRLD) Research & Development (2019 - 2026)

Prelude Therapeutics has disclosed Research & Development across 8 years of filings, most recently posting $13.6 million for Q1 2026.

• Research & Development for Q1 2026 came in at $13.6 million, down 52.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $79.1 million (down 33.77% YoY), and the FY2025 annual result was $94.3 million, down 20.08% from the prior year.
• Research & Development came in at $13.6 million for Q1 2026 at Prelude Therapeutics, down from $18.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $31.6 million in Q4 2024 to a low of $13.6 million in Q1 2026.
• The 5-year median for Research & Development is $25.8 million (2025), against an average of $24.8 million.
• Across the five-year window, Research & Development soared 38.56% in 2022 and plunged 52.8% in 2026, its largest moves.
• Prelude Therapeutics' Research & Development stood at $25.9 million in 2022, then advanced by 17.25% to $30.3 million in 2023, then increased by 4.25% to $31.6 million in 2024, then tumbled by 43.1% to $18.0 million in 2025, then slipped by 24.41% to $13.6 million in 2026.
• The last three Research & Development figures came in at $13.6 million (Q1 2026), $18.0 million (Q4 2025), and $21.7 million (Q3 2025), per Business Quant data.